Literature DB >> 19169059

Sympathovagal imbalance in transsexual subjects.

E Resmini1, M Casu, V Patrone, A Rebora, G Murialdo, F Minuto, D Ferone.   

Abstract

CONTEXT: Autonomic nervous system imbalance is related to cardiovascular risk. Heart rate variability (HRV) indexes are associated with age, race, and sex, but the role of sex hormones is still unknown.
OBJECTIVE: To evaluate sympathovagal balance (SB) in transsexuals. PATIENTS: Eighteen transsexual subjects, 12 male-to-female (group 1) and 6 female- to-male (group 2), compared with 34 age-matched controls: 17 males (group 3) and 17 females (group 4). Autonomic testing of SB was performed by Power Spectral Analysis (PSA) of HRV in clinostatism (c) and orthostatism (o). PSA identifies power peaks: high frequency (HF) expresses vagal activity, while low frequency (LF) expresses sympathetic activity.
RESULTS: Group 1 showed lower LFc than groups 2, 3, and 4 (p<0.001, p=0.05, p<0.001, respectively), and lower LFo than groups 3 and 4 (p=0.01); HFc was lower than in groups 2, 3, and 4 (p=0.02, p=0.02, p<0.001, respectively), and HFo was lower than in groups 3 and 4 (p<0.001). LFo/HFo ratio was higher in group 1 than in group 4 (p<0.001). No differences emerged between groups 2 and 3. Group 2 showed lower HFo than group 4 (p=0.03), and a higher LFo/HFo ratio (p=0.01). Group 3 showed lower HFo and HFc than group 4 (p=0.02, p=0.05, respectively), and a higher LFo/HFo ratio (p=0.03).
CONCLUSION: In this study we found a sympathovagal imbalance due to a reduced sympathetic and parasympathetic influence on heart rate. Sex hormone therapy per se may play a role in this imbalance, and HRV measurement could be useful in detecting cardiovascular risk in transsexuals.

Entities:  

Mesh:

Year:  2008        PMID: 19169059     DOI: 10.1007/BF03345641

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  29 in total

1.  Heart rate variability: from bench to bedside.

Authors:  Alberto Malliani
Journal:  Eur J Intern Med       Date:  2005-02       Impact factor: 4.487

2.  Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.

Authors: 
Journal:  Eur Heart J       Date:  1996-03       Impact factor: 29.983

Review 3.  Heart rate variability and its sympatho-vagal modulation.

Authors:  F Lombardi; A Malliani; M Pagani; S Cerutti
Journal:  Cardiovasc Res       Date:  1996-08       Impact factor: 10.787

4.  Gender differences in autonomic cardiovascular regulation: spectral, hormonal, and hemodynamic indexes.

Authors:  J M Evans; M G Ziegler; A R Patwardhan; J B Ott; C S Kim; F M Leonelli; C F Knapp
Journal:  J Appl Physiol (1985)       Date:  2001-12

Review 5.  Sympathetic--parasympathetic interaction and sudden death.

Authors:  E Vanoli; P J Schwartz
Journal:  Basic Res Cardiol       Date:  1990       Impact factor: 17.165

6.  Sympathovagal imbalance in acromegalic patients.

Authors:  Eugenia Resmini; Massimo Casu; Vittoriana Patrone; Giovanni Murialdo; Federico Bianchi; Massimo Giusti; Diego Ferone; Francesco Minuto
Journal:  J Clin Endocrinol Metab       Date:  2005-11-01       Impact factor: 5.958

7.  Differing effects of age on heart rate variability in men and women.

Authors:  P K Stein; R E Kleiger; J N Rottman
Journal:  Am J Cardiol       Date:  1997-08-01       Impact factor: 2.778

8.  Reduced heart rate variability and new-onset hypertension: insights into pathogenesis of hypertension: the Framingham Heart Study.

Authors:  J P Singh; M G Larson; H Tsuji; J C Evans; C J O'Donnell; D Levy
Journal:  Hypertension       Date:  1998-08       Impact factor: 10.190

Review 9.  Gender differences in the neurohumoral control of the cardiovascular system.

Authors:  Maria Rosa Conte
Journal:  Ital Heart J       Date:  2003-06

10.  Sex differences in the parasympathetic nerve control of rat heart.

Authors:  X J Du; A M Dart; R A Riemersma
Journal:  Clin Exp Pharmacol Physiol       Date:  1994-06       Impact factor: 2.557

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.